MAX-40279

DRUG3 trials

Sponsors

Maxinovel Pty., Ltd.

Conditions

Acute Myelogenous Leukemia (AML)Acute Myeloid LeukemiaGastric CancerGastroesophageal Junction Cancer

Phase 1

MAX-40279 in Subjects With Acute Myelogenous Leukemia (AML)

Maxinovel Pty., Ltd.Acute Myelogenous Leukemia (AML)

Start: 2018-08-01End: 2022-12-01Target: 30Updated: 2022-01-19

Phase 2

A Phase 2 Study to Evaluate the Safety and Efficacy of Max-40279-01 in Patients With Advanced Gastric Cancer or Gastroesophageal Junction Cancer

Maxinovel Pty., Ltd.Gastric Cancer, Gastroesophageal Junction Cancer

Start: 2022-06-30End: 2023-12-31Target: 30Updated: 2022-06-02

A Phase 2 Study of MAX-40279 Combined With Venetoclax and Azacitidine in Unfit Newly Diagnosed Acute Myeloid Leukemia

RecruitingNCT07743112

Maxinovel Pty., Ltd.Acute Myeloid Leukemia

Start: 2025-09-05End: 2027-12-01Target: 43Updated: 2026-08-03